Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for NovaBay Pharmaceuticals (NBY) over the last 16 years, with Q2 2025 value amounting to $4000.0.

  • NovaBay Pharmaceuticals' Share-based Compensation fell 9272.73% to $4000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $17000.0, marking a year-over-year decrease of 9251.1%. This contributed to the annual value of $148000.0 for FY2024, which is 4914.09% down from last year.
  • NovaBay Pharmaceuticals' Share-based Compensation amounted to $4000.0 in Q2 2025, which was down 9272.73% from $2000.0 recorded in Q1 2025.
  • In the past 5 years, NovaBay Pharmaceuticals' Share-based Compensation registered a high of $184000.0 during Q1 2022, and its lowest value of -$208000.0 during Q3 2022.
  • For the 5-year period, NovaBay Pharmaceuticals' Share-based Compensation averaged around $42375.0, with its median value being $61000.0 (2023).
  • As far as peak fluctuations go, NovaBay Pharmaceuticals' Share-based Compensation crashed by 16000.0% in 2021, and later surged by 23162.39% in 2022.
  • Over the past 5 years, NovaBay Pharmaceuticals' Share-based Compensation (Quarter) stood at -$117000.0 in 2021, then surged by 176.92% to $90000.0 in 2022, then changed by 0.0% to $90000.0 in 2023, then crashed by 87.78% to $11000.0 in 2024, then plummeted by 63.64% to $4000.0 in 2025.
  • Its Share-based Compensation was $4000.0 in Q2 2025, compared to $2000.0 in Q1 2025 and $11000.0 in Q4 2024.